柳氮磺胺吡啶与安慰剂治疗银屑病关节炎的比较。一项退伍军人事务部合作研究。
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.
作者信息
Clegg D O, Reda D J, Mejias E, Cannon G W, Weisman M H, Taylor T, Budiman-Mak E, Blackburn W D, Vasey F B, Mahowald M L, Cush J J, Schumacher H R, Silverman S L, Alepa F P, Luggen M E, Cohen M R, Makkena R, Haakenson C M, Ward R H, Manaster B J, Anderson R J, Ward J R, Henderson W G
机构信息
VAMC, Salt Lake City, Utah, USA.
出版信息
Arthritis Rheum. 1996 Dec;39(12):2013-20. doi: 10.1002/art.1780391210.
OBJECTIVE
To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy.
METHODS
Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments.
RESULTS
Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea.
CONCLUSION
SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.
目的
确定每日剂量为2000毫克的柳氮磺胺吡啶（SSZ）对治疗对非甾体抗炎药治疗耐药的活动性银屑病关节炎（PsA）是否有效。
方法
从15家诊所招募了221例PsA患者，随机（双盲）分为SSZ组或安慰剂组进行治疗，并随访36周。治疗反应基于关节疼痛/压痛和肿胀评分以及医生和患者的整体评估。
结果
纵向分析显示倾向于SSZ治疗的趋势（P = 0.13）。治疗结束时，SSZ组的反应率为57.8%，而安慰剂组为44.6%（P = 0.05）。服用SSZ的PsA患者的魏氏血沉率下降幅度大于服用安慰剂的患者（P < 0.0001）。不良反应比预期的少，主要是由于非特异性胃肠道不适，包括消化不良、恶心、呕吐和腹泻。
结论
每日剂量为2000毫克的SSZ耐受性良好，在治疗PsA患者方面可能比安慰剂更有效。
Zotero 插件